welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis
In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.
expertly curated content related to this topic
- Uri Ladabaum, MDUri Ladabaum, MD is a Professor of Medic...
- Elena Martinez Stoffel, MDAssistant Professor, Internal Medicine a...
- Ostomy: Diet and Nutrition GuideThis guide provides some basic informati...
- Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europ...Cancer Prevention Pharmaceuticals, Inc. ...
- Travis H. BrayTravis Bray is the Founder and Executive...
- Diagnosis, Surveillance, and Treatment Strategies For Familial Adenomatous Polyposis: Rationale and UpdateFamilial adenomatous polyposis is charac...
- Familial Adenomatous Polyposis (FAP): InheritedFAP is an inherited colorectal cancer sy...
English
Portuguese
Spanish